Lyterian Therapeutics
Betsy Martin is a Scientist II in Target Biology at Lyterian Therapeutics, bringing extensive experience in discovery biology research from BridgeBio, where Martin served as Lead Scientist and managed a team to develop a small molecule inhibitor for Autosomal dominant polycystic kidney disease. At BridgeBio, Martin also led an Antisense Oligonucleotide program for diffuse intrinsic pontine glioma, establishing key cellular assays for target knockdown efficacy. Prior to that, Martin was a Graduate Student Researcher at UCSF, focusing on DNA cytosine modifications in mouse embryonic stem cells, and held a Lab Manager position at UC Irvine. Martin's academic background includes a PhD in Biochemistry and Molecular Biology from UCSF and a Bachelor's degree in Biology from Claremont McKenna College.
This person is not in any offices
Lyterian Therapeutics
1 followers
Lyterian Therapeutics derives its name from the Greek word λυτήριος or lutḗrios, that defines the termination, healing, or end of disease. Disease resolution is coordinated by endogenous and exogenous agents that recruit cells and other effectors to the site of injury. We are inspired to learn from the logic that orchestrates homeostatic equilibria and fosters healing in response to disease. At Lyterian Therapeutics, we are committed to developing medicines for patients in need by co-opting physiologically relevant protein homeostatic mechanisms to regulate genetically validated targets.
Employees
1-10